- Home
- ADTX vs RDHL Comparison
ADTX vs RDHL Comparison
Compare ADTX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADTX
- RDHL
- Stock Information
- Founded
- ADTX 2017
- RDHL 2009
- Country
- ADTX United States
- RDHL Israel
- Employees
- ADTX N/A
- RDHL N/A
- Industry
- ADTX Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- ADTX Health Care
- RDHL Health Care
- Exchange
- ADTX Nasdaq
- RDHL Nasdaq
- Market Cap
- ADTX 4.9M
- RDHL 3.9M
- IPO Year
- ADTX 2020
- RDHL N/A
- Fundamental
- Price
- ADTX $1.01
- RDHL $1.70
- Analyst Decision
- ADTX
- RDHL
- Analyst Count
- ADTX 0
- RDHL 0
- Target Price
- ADTX N/A
- RDHL N/A
- AVG Volume (30 Days)
- ADTX 172.4K
- RDHL 43.1K
- Earning Date
- ADTX 11-17-2025
- RDHL 09-05-2025
- Dividend Yield
- ADTX N/A
- RDHL N/A
- EPS Growth
- ADTX N/A
- RDHL N/A
- EPS
- ADTX N/A
- RDHL N/A
- Revenue
- ADTX $12,051.00
- RDHL $9,550,000.00
- Revenue This Year
- ADTX $15,768.94
- RDHL $381.91
- Revenue Next Year
- ADTX N/A
- RDHL N/A
- P/E Ratio
- ADTX N/A
- RDHL N/A
- Revenue Growth
- ADTX N/A
- RDHL 157.62
- 52 Week Low
- ADTX $0.81
- RDHL $1.06
- 52 Week High
- ADTX $4,698.00
- RDHL $11.70
- Technical
- Relative Strength Index (RSI)
- ADTX 47.27
- RDHL 63.39
- Support Level
- ADTX $0.98
- RDHL $1.47
- Resistance Level
- ADTX $1.11
- RDHL $1.60
- Average True Range (ATR)
- ADTX 0.07
- RDHL 0.09
- MACD
- ADTX 0.01
- RDHL 0.04
- Stochastic Oscillator
- ADTX 54.34
- RDHL 97.98
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.